Castleman's Disease – NCI-04-C-0275
Dr. Robert Yarchoan
Principal Investigator
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial for patients with Castleman's disease. Click on the trial below for additional details, including a summary of primary eligibility, study outline, and information on how to contact Dr. Yarchoan and his staff directly.
You may also call the Clinical Studies Support Center at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
Patients are assigned to one of six treatment groups based on disease status.
Group I (observation only)
- Patients with asymptomatic disease undergo observation only, or observation in conjunction with highly active antiretroviral therapy (HAART), where appropriate
Group II (high-dose zidovudine [HDAZT] and valganciclovir [VGCV])
- Patients with symptomatic disease that is not life-threatening receive oral HDAZT four times daily and oral VGCV twice daily on Days 1–21; courses repeat every 21 days
Group III (bortezomib, HDAZT, and VGCV)
- Patients with continued symptomatic disease who are not responding to group II therapy receive bortezomib IV over 3–5 seconds on Days 1, 4, 8, and 11 and HDAZT and VGCV as in group II on Days 1–21
- Courses repeat every 21 days
Group IV (EPOCH-R)
- Patients with life-threatening disease will receive EPOCH-R therapy comprising a 5-day course of rituximab, etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone
- Treatment repeats every 21 days for up to 6 courses
Group V
- Patients may also receive rituximab IV and doxorubicin hydrochloride liposome IV for 3 to 6 courses followed by interferon alpha maintenance for 6 to 12 months
Group VI
- Patients may also receive oral sirolimus daily with cycle length every 21 days
Why is this trial important?
This trial is important because KSHV-associated multicentric Castleman's disease is a poorly understood condition, and there is no standard medical treatment for the disease. This trial is designed to gather information about the disease and to develop new treatment strategies for the disease. The interventions being studied in this trial may have application to other rare diseases if they appear to be effective in this trial.
Back to Top
